ArticleJTCVS techniques2026
Optimizing long-term outcomes in pediatric mitral valve repair: A focus on posterior leaflet augmentation.
Article in JTCVS techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate mid- and long-term outcomes of posterior leaflet augmentation with fresh autologous pericardium for congenital or acquired mitral regurgitation in pediatric populations, and to identify predictors of valve-related reintervention. Methods: A retrospective review was conducted on all patients who underwent mitral valve repair, including posterior leaflet augmentation, at Bambino Gesù Children's Hospital between 2011 and 2024. Patients with atrioventricular septal defects or single-ventricle physiology were excluded. Demographic, operative, and echocardiographic data were analyzed. Freedom from reintervention was estimated using Kaplan-Meier analysis and risk factors were identified by Cox proportional hazards modeling. Results: Twenty-eight patients (median age, 3.8 years; interquartile range, 0.6-9.2 years; 57% men) underwent posterior leaflet augmentation using fresh autologous pericardium. Congenital mitral dysplasia was the most common etiology (50%), followed by rheumatic disease (29%). Mean preoperative mitral regurgitation grade was 3.9 ± 0.6, decreasing to 1.4 ± 0.5 postoperatively, and remained stable during follow-up (mean residual mitral regurgitation, 1.7 ± 0.7 mm Hg). Mean transmitral gradient increased from 2.5 ± 1.8 mm Hg to 4.2 ± 2.1 mm Hg, remaining stable over time (4.9 ± 2.2 mm Hg at last follow-up). During a median follow-up of 7.7 years (interquartile range, 6.6-10.5 years), 9 patients (32%) required reintervention, all consisting of mitral valve replacement. Freedom from reintervention was 84.9% at 1 year, 75.9% at 5 years, and 54.2% at 10 years. A postoperative mean gradient >5 mm Hg was the only independent predictor of reintervention (hazard ratio, 7.81; 95% CI, 1.9-31.4; Conclusions: Posterior leaflet augmentation with fresh autologous pericardium provides a durable, growth-preserving, and physiologic repair for pediatric mitral valve disease predominantly presenting with severe regurgitation. A postoperative transmitral gradient >5 mm Hg identifies patients at higher risk for late mitral valve replacement, emphasizing the importance of accurate intraoperative tailoring and early echocardiographic follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.